Track where you inject each week so you never have to guess
We believe in supporting each patients journeys with a simple, straightforward approach
Participants were randomly assigned in a 1:1:1:3 ratio to receive subcutaneous injections of tirzepatide once per week at doses of 5 mg, 10 mg, or 15 mg, or insulin glargine (100 U/mL)
Consequently, seeing a reduction in risk of cardiovascular events is promising, albeit not surprising. Jackie DesJardin, MD, a cardiologist and an assistant clinical professor of medicine at the University of California San Franciscos Division of Cardiology, cautioned that there may be more to these results than simply the medications
Many people who lose weight still have measurable apnea afterward, because anatomy and other factors do not fully reverse with weight loss alone